FH and lung carcinoma: Interestingly, sera from patients with early stage, non-metastatic, non-small cell lung cancer were found to contain autoantibodies against FH, where these recognize a conformationally distinct (reduced) form of the protein that is believed to be displayed only on the surface of tumor cells [180]; the autoantibodies interact with CCP 19 and inhibit the binding of FH to lung carcinoma cells, thereby promoting the deposition of C3b and increasing complement mediated tumor cell lysis.